Investors are feeling the pinch as NurExone Biologic Inc. faces a notable decline in its stock price.
NurExone Biologic Inc. (NRX.V) is experiencing a downturn in its stock price, dropping by 3.23% in today’s trading session. This decline raises questions about the company’s current market position and future prospects.
Advertisement
NurExone Biologic Inc.
NRX.V
NRX.V
NurExone Biologic Inc.
WealthAwesomeMarket cap
$57.07M
52W high
$1.14
52W low
$0.43
1W change
+30.53%
Beta
0.39
Analyst Price Targets
Based on analyst covering NRX
Wall Street analysts forecast NRX stock price to rise 301.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.49
+301.8% Upside
Current Price
C$0.62
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NRX's historical volatility
30-Day Vol
98.1%
Annualized
90-Day Vol
74.3%
Annualized
Trend (90d)
-13.3%
Annualized drift
90d Mean
C$0.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.61 | C$0.44 – C$0.86 |
| 60 trading days | C$0.60 | C$0.37 – C$0.97 |
| 90 trading days | C$0.59 | C$0.33 – C$1.06 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of approximately CA$57 million and no current profit margin, investors should carefully consider the implications of this drop before making further investment decisions.
NurExone's stock price falls to CA$0.60
The stock has decreased by 3.23% today, reflecting investor skepticism amid a challenging market environment.
Bull case
NurExone is focused on developing innovative exosome-based therapies for serious medical conditions. If successful, these therapies could offer significant long-term benefits.
Bear case
The recent decline in stock price, along with a lack of substantial news or financial results to boost investor confidence, may suggest deeper issues within the company’s operational strategy.
Market Reaction
Advertisement
NurExone's stock price fell to CA$0.60, reflecting a 3.23% decrease today. This decline comes amid a lack of significant news that could have otherwise buoyed investor sentiment. As the company focuses on developing exosome-based therapies, the market's reaction suggests a cautious approach from investors.
Company Overview
NurExone Biologic Inc. is dedicated to creating regenerative therapies targeting central nervous system injuries. Despite its innovative approach, the company currently faces challenges, including a market cap of CA$57 million and a profit margin of zero. Investors should evaluate the potential risks associated with this stock, especially in light of today's performance.
Looking Ahead
As NurExone continues to navigate the complexities of the biotechnology sector, investors should keep an eye on upcoming announcements and financial results. The company's ability to regain investor confidence will be crucial in determining its future stock performance. For more insights, check out our detailed analysis on NurExone's financial results and market trends.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
